-
Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track
Tuesday, January 8, 2019 - 3:11pm | 363Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the...
-
Morgan Stanley: Moderna Has Significant Competitive Advantage
Wednesday, January 2, 2019 - 5:30pm | 402Moderna Inc (NASDAQ: MRNA), a messenger RNA therapeutics company, recently offered 26.28 million shares priced at $23 each in an IPO. The Analyst Morgan Stanley analyst Matthew Harrison initiated coverage of Moderna with an Overweight rating and $29 price target. The Thesis Moderna has...
-
Sell-Side Slashes DBV Tech Price Targets After Withdrawal Of BLA For Peanut Allergy Immunotherapy
Thursday, December 20, 2018 - 11:00am | 607DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) shares were losing more than half of their value in Thursday trading following an update on the company's lead pipeline candidate. What Happened DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application,...
-
Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate
Wednesday, August 1, 2018 - 10:03am | 437A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded program’s stumble. The Analyst Analyst Matthew Harrison upgraded...
-
Cytokinetics Downgraded On Data Delay
Wednesday, August 1, 2018 - 9:39am | 381Biopharma Cytokinetics Inc. (NASDAQ: CYTK) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. The Analysts Morgan Stanley's Matthew Harrison downgraded Cytokinetics from Overweight to Equal-Weight and lowered...
-
Morgan Stanley: Newly Public Neon Therapeutics Has Outperformance Potential
Monday, July 23, 2018 - 2:42pm | 487Neon Therapeutics Inc (NASDAQ: NTGN) develops vaccine based on neoantigens — markers unique to each individual tumor — to improve tumor response in checkpoint inhibitors such as Merck & Co., Inc. (NYSE: MRK)'s Keytruda and Bristol-Myers Squibb Co (NYSE: BMY)...
-
Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target
Friday, July 13, 2018 - 12:45pm | 417Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The candidate also posted positive results in a late-stage trial that...
-
Incyte Has Limited Catalysts In Next 6 Months; But 2019 Could Be Pivotal, Morgan Stanley Says In Downgrade
Friday, July 13, 2018 - 10:16am | 369Incyte Corporation (NASDAQ: INCY)'s pipeline is devoid of any major catalysts in 2018, according to Morgan Stanley. The Analyst Analyst Matthew Harrison downgraded Incyte from Overweight to Equal-weight and maintained a $76 price target. The Thesis Many of Incyte's...
-
Evelo Biosciences' Potential Is 'Significant,' Says Bullish Morgan Stanley
Monday, June 4, 2018 - 8:53am | 393Evelo Biosciences Inc (NASDAQ: EVLO), a clinical stage biotechnology company that focuses on mining the gut for therapetuics that can modulate the immune system, boasts "significant" platform potential, according to Morgan Stanley. The Analyst Morgan Stanley's Matthew Harrison...
-
Unity Biotech Is A Buy On 'Novel Biology,' Morgan Stanley Says In Positive Initiation
Tuesday, May 29, 2018 - 4:04pm | 298Unity Biotechnology Inc (NASDAQ: UBX) has fallen 22 percent since its May 3 initial public offering. Nonetheless, three sell-side firms initiated price targets implying significant upside Tuesday. The Rating Morgan Stanley analysts Matthew Harrison and David Lebowitz initiated coverage on Unity...
-
Morgan Stanley Upgrades Loxo On The Potential Of A Targeted Cancer Therapy
Monday, April 16, 2018 - 9:52am | 449Loxo Oncology Inc (NASDAQ: LOXO) holds an opportunity to differentiate itself among RET inhibitors while developing medicines for patients with genetically defined cancers, according to Morgan Stanley. RET, or rearranged during transfection, is a certain type of mutation in protein that...
-
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
Wednesday, March 21, 2018 - 11:59am | 689Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded the following: Sarepta Therapeutics Inc (NASDAQ: SRPT) from Overweight to Sector Weight...
-
FDA Risk For Portola Pharma's Thrombosis Treatment Sends Morgan Stanley To Sideline
Thursday, March 1, 2018 - 12:01pm | 400Portola Pharmaceuticals Inc (NASDAQ: PTLA) plunged Thursday after the release of its fourth-quarter results. The company reported a narrower-than-expected loss for Q4 and provided a corporate update. The Analyst Morgan Stanley analyst Matthew Harrison downgraded shares of Portola Pharma from...
-
Morgan Stanley Gets Wise On Sage Therapeutics, Initiates With A Buy
Monday, February 26, 2018 - 10:21am | 333SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals. It found further reason to celebrate Monday with the conversion of a new Street advocate. The Rating Morgan Stanley...
-
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
Thursday, February 8, 2018 - 10:41am | 2179"Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent estimates indicate it may now be the third most common cause of death, behind heart disease...